Edition:
United Kingdom

Teijin Ltd (3401.T)

3401.T on Tokyo Stock Exchange

2,401JPY
15 Dec 2017
Change (% chg)

¥-23 (-0.95%)
Prev Close
¥2,424
Open
¥2,423
Day's High
¥2,435
Day's Low
¥2,395
Volume
1,549,200
Avg. Vol
1,637,759
52-wk High
¥2,498
52-wk Low
¥2,018

Select another date:

Thu, Nov 30 2017

BRIEF-Teijin To Invest 35 Billion Yen To Build Carbon Fiber Plant In U.S. -Nikkei

* TEIJIN TO INVEST 35 BILLION YEN TO BUILD CARBON FIBER PLANT IN U.S. -NIKKEI Source text: (http://s.nikkei.com/2Al5U6z) Further company coverage:

BRIEF-Teijin to merge with fiber unit

* Says it will merge with a Tokyo-based fiber consolidated subsidiary

BRIEF-R&I affirms Teijin's rating at "A-" and says stable outlook -R&I

* Says Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A-" -R&I

BRIEF-Teijin lowers conversion price for 2018 due euro-yen denominated convertible bonds and 2021 due euro-yen denominated convertible bonds

* Says it lowered the conversion price for 2018 due euro-yen denominated convertible bonds to 2,026 yen per share, from 2,035.7 yen per share, after Oct. 1

BRIEF-Merz, Teijin announce partnership to bring Xeomin to Japan

* Merz and Teijin announce partnership to bring Xeomin (Incobotulinumtoxina) to Japan

BRIEF- Teijin to transfer rights and obligations to unit TEIJIN FRONTIER

* Says it will transfer rights and obligations, including inventories, investment securities and capital invested into group company, to wholly owned unit TEIJIN FRONTIER CO., LTD.

BRIEF- JCR Pharmaceuticals to develop allogeneic regenerative medical product using DPCs with Teijin

* Says it entered into co-development and license agreement with Teijin Ltd, regarding JTR-161, an allogeneic regenerative medical product using dental pulp stem cells (DPCs) for the indication of acute cerebral infarction (stroke) for Japan, on July 18

BRIEF-Teijin invests in its twaron capacity in Dutch production facility

* Teijin invests in its twaron capacity in Dutch production facility

BRIEF-Radius Health announces license and development agreement for Abaloparatide-Sc with Teijin Limited in Japan

* Radius Health announces license and development agreement for Abaloparatide-Sc with Teijin Limited in Japan

Select another date: